The INSULIN Act of 2026 aims to reduce insulin prices and protect patients by setting cost-sharing limits, expediting biosimilar competition, and.

The INSULIN Act of 2026 seeks to lower insulin prices and protect patients by establishing cost-sharing limits for certain insulin products in group health plans and health insurance coverage. It mandates that selected insulin products cannot have deductibles or cost-sharing above $35 per 30-day supply. The Act also aims to expedite the development and review of biosimilar biological products to increase competition and affordability. Additionally, it establishes a resource center to assist uninsured individuals in accessing affordable insulin, and mandates a study on uninsured insulin users.

The INSULIN Act of 2026 aims to reduce insulin prices and protect patients by setting cost-sharing limits, expediting biosimilar competition, and.

The INSULIN Act of 2026 seeks to lower insulin prices and protect patients by establishing cost-sharing limits for certain insulin products in group health plans and health insurance coverage. It mandates that selected insulin products cannot have deductibles or cost-sharing above $35 per 30-day supply. The Act also aims to expedite the development and review of biosimilar biological products to increase competition and affordability. Additionally, it establishes a resource center to assist uninsured individuals in accessing affordable insulin, and mandates a study on uninsured insulin users.